Saturday - July 04, 2026

Category Archives: Science

Small Lymphocytic Lymphoma Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and non-clinical stage products. It … Continue reading →

Knee Osteoarthritis Pipeline Gains Momentum: 55+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Knee Osteoarthritis Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 65+ pipeline drugs in the Knee Osteoarthritis pipeline landscape. It covers the Knee Osteoarthritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Muscle-Invasive Bladder Cancer Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Muscle Invasive Bladder Cancer pipeline landscape. It covers the Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and … Continue reading →

Thyroid Cancer Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Cutaneous Squamous Cell Carcinoma Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Cutaneous Squamous Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Cutaneous Squamous Cell Carcinoma pipeline landscape. It covers the Cutaneous Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical … Continue reading →

Reclaiming Focus in the Age of Endless Scrolling: Bellevue Therapist Beverly Brashen, Ph.D. on What Constant Screen Time Is Doing to Our Brains and How to Reverse It

Designed-for-addiction platforms are quietly eroding our capacity to concentrate, remember, and think creatively. But focus, like any skill, can be retrained. Designed-for-addiction platforms are quietly eroding our capacity to concentrate, remember, and think creatively. But focus, like any skill, can … Continue reading →

Treatment-Resistant Hypertension (TRH) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Treatment-Resistant Hypertension (TRH) is witnessing steady growth driven by the increasing prevalence of hypertension, growing burden of obesity, diabetes, and chronic kidney disease, improving diagnosis rates, and the introduction of novel antihypertensive therapies. Additionally, the launch … Continue reading →

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Market is Projected to Witness Significant Growth by 2036 Owing to the Launch of Novel Menin Inhibitors and Targeted Therapies | DelveInsight

The market dynamics for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) are witnessing significant growth driven by the increasing incidence of acute myeloid leukemia, rising adoption of precision medicine, expanding use of mutation-targeted therapies, and a robust pipeline of novel immunotherapies … Continue reading →

c-MET-NSCLC Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET+ NSCLC pipeline drug profiles, including … Continue reading →